Morbus Basedow

Der Morbus Basedow ist nach der Schilddrüsenautonomie die häufigste Ursache einer Hyperthyreose in Deutschland. Die Inzidenz liegt bei ca. 40/100 000 Einwohner. Am häufigsten ist die Altersgruppe zwischen 20 und 50 Jahren betroffen. Diagnostik- und Therapieempfehlungen in diesem Beitrag basieren u. a. auf europäischen und internationalen Empfehlungen.

Abstract

Diagnosis The diagnosis of Gravesʼ disease is mainly based on ultrasonography and laboratory diagnostics. This includes the determination of the TSH value and the peripheral thyroid hormones. TSH receptor antibody (TRAb) measurement is highly sensitive and specific for the detection of Gravesʼ disease (GD) and helps to distinguish from autoimmune thyroiditis (AIT). However, as recent studies show, some may AIT patients may also reveal TRAb.

Therapy Current guidelines recommend primarily the use of thiamazol/carbimazole in GD. Due to the comparatively higher hepatotoxicity, propylthiouracil is not recommended as first line therapy. In case of relapse during 12 up to 18 months of antithyroid drug therapy or after a frustrating attempt at cessation, definitive therapy should be considered. Alternatively, in accordance with the current recommendations of the European Thyroid Association, drug therapy may be continued for up to 12 months after initial diagnosis.

Pregnancy The treatment of active GD during pregnancy is problematic due to diaplacental crossing of peripheral thyroid hormones, TSH receptor stimulating antibodies and antithyroid drugs. According to current guidelines, PTU is recommended during the first 16 weeks of pregnancy, whereas for the 2nd and 3 rd trimester no special recommendations are given. After that, you can choose which antithyroid drug might be used. The aim of antithyroid drug therapy during pregnancy is to achieve a suppressed TSH value together with normal or slightly increased fT4 while using lowest effective dose of antithyroid drug.

Immune checkpoint inhibitors (ICI) The most common endocrine side effect with this therapy is thyroid dysfunction. Hyperthyroidism; occur most frequently in combination therapy (CTLA-4 / anti-PD-1 therapy) ICI mainly causes destructive thyroiditis with lymphocytic infiltration; GD is absolutely rare in this context and only few cases are described.

Schlüsselwörter

Morbus Basedow - Hyperthyreose - TSH-Rezeptor-Antikörper

Key words

Gravesʼ disease - hyperthyroidism - TSH receptor antibodies

Publication History

Article published online:
13 October 2021

• Literatur

• 1 Furmaniak J, Sanders J, Nunez MR. et al. Mechanisms of Action of TSHR Autoantibodies. Horm Metab Res 2015; 47: 735-752 DOI: 10.1055/s-0035-1559648.
• 2 Petersen M, Bulow Pedersen I, Knudsen N. et al. Changes in subtypes of overt thyrotoxicosis and hypothyroidism following iodine fortification. Clin Endocrinol (Oxf) 2019; 91: 652-659 DOI: 10.1111/cen.14072.
• 3 Schott M, Feldkamp J, Bathan C. et al. Detecting TSH-receptor antibodies with the recombinant TBII assay: technical and clinical evaluation. Horm Metab Res 2000; 32: 429-435 DOI: 10.1055/s-2007-978666.
• 4 Stasiak M, Michalak R, Stasiak B. et al. Clinical characteristics of subacute thyroiditis is different than it used to be – current state based on 15 years own material. Neuro Endocrinol Lett 2019; 39: 489-495
• 5 Diederich S, Feldkamp J, Grußendorf M. et al. Referenz Endokrinologie und Diabetologie. 1. Auflage.. Stuttgart: Thieme; 2020
• 6 Kahaly GJ, Bartalena L, Hegedus L. et al. 2018 European Thyroid Association Guideline for the Management of Gravesʼ Hyperthyroidism. Eur Thyroid J 2018; 7: 167-186 DOI: 10.1159/000490384.
• 7 Abraham P, Avenell A, McGeoch SC. et al. Antithyroid drug regimen for treating Gravesʼ hyperthyroidism. Cochrane Database Syst Rev 2010; pub4: CD003420 DOI: 10.1002/14651858.CD003420.
• 8 Isozaki O, Satoh T, Wakino S. et al. Treatment and management of thyroid storm: analysis of the nationwide surveys. Clin Endocrinol (Oxf) 2016; 84: 912-918 DOI: 10.1111/cen.12949.
• 9 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26: 1343-1421 DOI: 10.1089/thy.2016.0229.
• 10 Bartalena L, Piantanida E, Tanda ML. Methimazole Treatment and Acute Pancreatitis: Both Caution and Reassurance Are Needed. J Clin Endocrinol Metab 2020; DOI: 10.1210/clinem/dgaa636.
• 11 Sjolin G, Holmberg M, Torring O. et al. The Long-Term Outcome of Treatment for Gravesʼ Hyperthyroidism. Thyroid 2019; 29: 1545-1557 DOI: 10.1089/thy.2019.0085.
• 12 Brito JP, Payne S, Singh Ospina N. et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Gravesʼ Disease: A Nationwide Population-Based Study. Thyroid 2020; 30: 357-364 DOI: 10.1089/thy.2019.0132.
• 13 Mohlin E, Filipsson Nystrom H, Eliasson M. Long-term prognosis after medical treatment of Gravesʼ disease in a northern Swedish population 2000–2010. Eur J Endocrinol 2014; 170: 419-427 DOI: 10.1530/EJE-13-0811.
• 14 Schott M, Morgenthaler NG, Fritzen R. et al. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Gravesʼ disease. Horm Metab Res 2004; 36: 92-96 DOI: 10.1055/s-2004-814217.
• 15 Azizi F, Amouzegar A, Tohidi M. et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Gravesʼ Disease: Results of a Randomized Clinical Trial. Thyroid 2019; 29: 1192-1200 DOI: 10.1089/thy.2019.0180.
• 16 Alexander EK, Pearce EN, Brent GA. et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27: 315-389 DOI: 10.1089/thy.2016.0457.
• 17 Scappaticcio L, Pitoia F, Esposito K. et al. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord 2020; 2020: 1-13 DOI: 10.1007/s11154-020-09615-z.
• 18 Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Gravesʼ disease after COVID-19. J Endocrinol Invest 2020; 43: 1527-1528 DOI: 10.1007/s40618-020-01366-7.
• 19 Bartalena L, Chiovato L, Marcocci C. et al. Management of Gravesʼ hyperthyroidism and orbitopathy in time of COVID-19 pandemic. J Endocrinol Invest 2020; 43: 1149-1151 DOI: 10.1007/s40618-020-01293-7.
• 20 Chang LS, Barroso-Sousa R, Tolaney SM. et al. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 2019; 40: 17-65 DOI: 10.1210/er.2018-00006.